---
title: Dextropropoxyphene + Nimesulide + Paracetamol
description: >-
  Dextropropoxyphene + Nimesulide + Paracetamol is indicated for the short-term
  management of acute pain, such as post-operative pain, acute musculoskeletal
  pain, and other short-term painful conditions.  It is an analgesic, meaning it
  relieves pain.
is_banned: false
lastModified: '2025-09-22T17:22:09.001Z'
faqs:
  - q: >-
      What is the recommended dosage for Dextropropoxyphene + Nimesulide +
      Paracetamol?**

      **A:**  Adult dosage varies; typically, one tablet every 6-8 hours as
      needed. Not recommended for children below 12 years.  Dosage must be
      adjusted for patients with renal or hepatic impairment and the elderly.
    a: >-
      A:**  Adult dosage varies; typically, one tablet every 6-8 hours as
      needed. Not recommended for children below 12 years.  Dosage must be
      adjusted for patients with renal or hepatic impairment and the elderly.
  - q: |-
      What are the common side effects?**
      **A:** Nausea, vomiting, constipation, dizziness, drowsiness.
    a: 'A:** Nausea, vomiting, constipation, dizziness, drowsiness.'
  - q: >-
      Is this combination safe during pregnancy?**

      **A:** Generally avoided, particularly in the third trimester, due to
      potential fetal risks.
    a: >-
      A:** Generally avoided, particularly in the third trimester, due to
      potential fetal risks.
  - q: >-
      Can I take this medication while breastfeeding?**

      **A:**  Not recommended, as dextropropoxyphene and nimesulide can be
      excreted in breast milk and potentially harm the infant.
    a: >-
      A:**  Not recommended, as dextropropoxyphene and nimesulide can be
      excreted in breast milk and potentially harm the infant.
  - q: |-
      What are the serious side effects I should be aware of?**
      **A:** Hepatotoxicity, respiratory depression, allergic reactions.
    a: 'A:** Hepatotoxicity, respiratory depression, allergic reactions.'
  - q: >-
      What are the contraindications for this medication?**

      **A:** Hypersensitivity, severe respiratory or hepatic impairment, active
      peptic ulcer, pregnancy, breastfeeding, children below 12 years.
    a: >-
      A:** Hypersensitivity, severe respiratory or hepatic impairment, active
      peptic ulcer, pregnancy, breastfeeding, children below 12 years.
  - q: >-
      Does this drug interact with alcohol?**

      **A:** Yes, avoid alcohol while taking this medication due to increased
      risks of liver damage and enhanced sedation.
    a: >-
      A:** Yes, avoid alcohol while taking this medication due to increased
      risks of liver damage and enhanced sedation.
  - q: >-
      What are the key drug interactions to consider?**

      **A:** Other opioids, benzodiazepines, antidepressants, CYP3A4 inhibitors,
      anticoagulants.
    a: >-
      A:** Other opioids, benzodiazepines, antidepressants, CYP3A4 inhibitors,
      anticoagulants.
  - q: |-
      What should I monitor in patients taking this combination?**
      **A:** Liver function tests, renal function tests, respiratory rate.
    a: 'A:** Liver function tests, renal function tests, respiratory rate.'
---
## **Usage**

Dextropropoxyphene + Nimesulide + Paracetamol is indicated for the short-term management of acute pain, such as post-operative pain, acute musculoskeletal pain, and other short-term painful conditions.  It is an analgesic, meaning it relieves pain.

This combination medication works through multiple pathways to address pain and inflammation.  Paracetamol is thought to act primarily in the central nervous system, increasing the pain threshold. It also has antipyretic properties. Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, which are involved in inflammation and pain. Dextropropoxyphene is an opioid analgesic that binds to opioid receptors in the central nervous system, altering pain perception.

## **Alternate Names**

No internationally recognized non-proprietary name exists for this specific combination.  However, the individual components are well-known:  paracetamol (also known as acetaminophen), nimesulide, and dextropropoxyphene. Brand names vary depending on the manufacturer and region, with "Nimodex" and "Orthodex" being reported.

## **How It Works**

**Pharmacodynamics:** This combination exerts its analgesic and antipyretic effects through the combined action of its components. Paracetamol's precise mechanism is not fully understood but involves central action. Nimesulide inhibits COX enzymes, particularly COX-2, thereby reducing prostaglandin synthesis. Dextropropoxyphene acts on opioid receptors, modulating pain pathways.

**Pharmacokinetics:** Each component has its own pharmacokinetic profile. Paracetamol is rapidly absorbed after oral administration, metabolized in the liver primarily through glucuronidation and sulfation, and excreted renally. Nimesulide is also well-absorbed orally, metabolized in the liver primarily by CYP2C9, and excreted via the kidneys.  Dextropropoxyphene is metabolized in the liver, primarily by CYP3A4, to its major active metabolite nordextropropoxyphene, and excreted via the kidneys.


## **Dosage**

### **Standard Dosage**

#### **Adults:**

A typical adult dose is one tablet every 6-8 hours as needed for pain, not to exceed a specified maximum daily dose. Due to the inclusion of dextropropoxyphene, an opioid analgesic, it is important to adhere to prescribed dosages and avoid exceeding the recommended limits.  The dosage may be adjusted according to the patient's pain severity and response to therapy. This combination should be prescribed for short-term use only due to risks associated with long-term opioid use. Nimesulide has also been associated with liver toxicity and is generally not recommended for long-term use.


#### **Children:**

This drug is not recommended for use in children below 12 years of age due to the potential for serious adverse effects, particularly related to dextropropoxyphene and nimesulide.

#### **Special Cases:**

* **Elderly Patients**: Dose adjustments may be required due to age-related decreases in renal and hepatic function. Start with a lower dose and titrate up cautiously as needed. Closely monitor for side effects.

* **Patients with Renal Impairment**: Dose reduction and close monitoring are essential.  Both nimesulide and dextropropoxyphene are primarily excreted renally, hence their accumulation can occur with impaired renal function.

* **Patients with Hepatic Dysfunction**: Dose modification is crucial as both paracetamol and nimesulide are metabolized in the liver. Caution is advised in patients with any degree of liver dysfunction. Nimesulide, in particular, carries a risk of hepatotoxicity and should be used with extreme caution, if at all, in such patients.

* **Patients with Comorbid Conditions**: Evaluate for potential interactions with existing conditions and adjust dosage accordingly. Exercise extreme caution in patients with respiratory conditions, as dextropropoxyphene can cause respiratory depression.

### **Clinical Use Cases**

The combination of dextropropoxyphene, nimesulide, and paracetamol is not generally recommended for specific clinical scenarios like intubation, surgical procedures, mechanical ventilation, ICU use, or emergency situations. Other analgesics or anesthetic agents are preferred in these settings.

### **Dosage Adjustments**

Dosage adjustments should be made based on the individual patient's renal function, hepatic function, comorbidities, and response to therapy.  Always start with the lowest effective dose and titrate upwards carefully.

## **Side Effects**

### **Common Side Effects**

Nausea, vomiting, constipation, dizziness, drowsiness, and changes in mood.

### **Rare but Serious Side Effects**

Hepatotoxicity (especially with nimesulide), respiratory depression (with dextropropoxyphene), allergic reactions, gastrointestinal bleeding, Stevens-Johnson syndrome.

### **Long-Term Effects**

Chronic opioid use can lead to dependence, tolerance, and withdrawal symptoms. Prolonged use of nimesulide can increase the risk of cardiovascular and renal complications.


### **Adverse Drug Reactions (ADR)**

Severe hepatotoxicity, anaphylaxis, respiratory arrest, cardiac arrhythmias.

## **Contraindications**

Hypersensitivity to any component, severe respiratory depression, acute or severe bronchial asthma, paralytic ileus, severe hepatic impairment, severe renal impairment, active peptic ulcer, gastrointestinal bleeding, history of drug addiction, concurrent use with other opioids or MAO inhibitors, children below 12 years of age.

## **Drug Interactions**

Alcohol, other opioids (increased risk of respiratory depression), benzodiazepines (increased sedation), antidepressants (serotonin syndrome risk), CYP3A4 and CYP2D6 inhibitors (increased dextropropoxyphene levels), anticoagulants (increased bleeding risk).  

## **Pregnancy and Breastfeeding**

This combination is generally not recommended during pregnancy, particularly in the third trimester, due to the potential risks to the fetus.  Dextropropoxyphene should be avoided during breastfeeding. Nimesulide should also generally be avoided during pregnancy and breastfeeding. It's crucial to weigh the benefits and risks before prescribing this combination to pregnant or breastfeeding women. Safer alternative analgesics should be considered.

## **Drug Profile Summary**

* **Mechanism of Action:** Analgesic and antipyretic via central and peripheral mechanisms; involves COX inhibition, opioid receptor binding, and modulation of central pain pathways.
* **Side Effects:** Nausea, vomiting, constipation, dizziness, drowsiness, hepatotoxicity, respiratory depression.
* **Contraindications:** Hypersensitivity, severe respiratory or hepatic impairment, active peptic ulcer, pregnancy (especially third trimester), breastfeeding.
* **Drug Interactions:** Alcohol, other opioids, benzodiazepines, antidepressants, CYP3A4 inhibitors.
* **Pregnancy & Breastfeeding:**  Generally avoided.
* **Dosage:** Adult dosage varies based on need and individual patient factors. Not recommended for children below 12 years.
* **Monitoring Parameters:** Liver function tests, renal function tests, respiratory rate.

## **Popular Combinations**

The combination of dextropropoxyphene, nimesulide, and paracetamol itself represents a multi-drug approach for pain relief.  Generally, combining this formulation with other analgesics is not recommended due to the potential for increased adverse events and drug interactions.

## **Precautions**

Assess for allergies, hepatic and renal function, and respiratory status before initiating therapy.  Avoid alcohol. Caution in patients with cardiovascular disease.  Monitor for signs of respiratory depression and hepatotoxicity.

## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Dextropropoxyphene + Nimesulide + Paracetamol?**
**A:**  Adult dosage varies; typically, one tablet every 6-8 hours as needed. Not recommended for children below 12 years.  Dosage must be adjusted for patients with renal or hepatic impairment and the elderly.

### **Q2:  What are the common side effects?**
**A:** Nausea, vomiting, constipation, dizziness, drowsiness.

### **Q3:  Is this combination safe during pregnancy?**
**A:** Generally avoided, particularly in the third trimester, due to potential fetal risks.

### **Q4:  Can I take this medication while breastfeeding?**
**A:**  Not recommended, as dextropropoxyphene and nimesulide can be excreted in breast milk and potentially harm the infant.

### **Q5:  What are the serious side effects I should be aware of?**
**A:** Hepatotoxicity, respiratory depression, allergic reactions.

### **Q6: What are the contraindications for this medication?**
**A:** Hypersensitivity, severe respiratory or hepatic impairment, active peptic ulcer, pregnancy, breastfeeding, children below 12 years.

### **Q7:  Does this drug interact with alcohol?**
**A:** Yes, avoid alcohol while taking this medication due to increased risks of liver damage and enhanced sedation.

### **Q8: What are the key drug interactions to consider?**
**A:** Other opioids, benzodiazepines, antidepressants, CYP3A4 inhibitors, anticoagulants.

### **Q9:  What should I monitor in patients taking this combination?**
**A:** Liver function tests, renal function tests, respiratory rate.



